Vistagen Therapeutics公布了一项积极进展:其核心药物Fasedienol在临床试验中,于主要终点及次要终点均观察到了明确的疗效信号。这一发现为这一候选疗法增添了新的希望,也标志着公司在焦虑症治疗领域迈出了关键一步。该疗效信号的显现,意味着药物不仅在预设的主要评估指标上表现突出,还在一系列辅助性指标上同步验证了其治疗潜力。
Vistagen Therapeutics公布了一项积极进展:其核心药物Fasedienol在临床试验中,于主要终点及次要终点均观察到了明确的疗效信号。这一发现为这一候选疗法增添了新的希望,也标志着公司在焦虑症治疗领域迈出了关键一步。该疗效信号的显现,意味着药物不仅在预设的主要评估指标上表现突出,还在一系列辅助性指标上同步验证了其治疗潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.